Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration

Tabernilla Andres; Grandal Marta; Pernas Berta; Castro-Iglesias Angeles; Rodriguez-Osorio Iria; Mena Alvaro; Delgado Manuel; Cid Purificacion; Pedreira Jose D.; Poveda Eva

首页> 外文期刊>European journal of gastroenterology and hepatology >Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration

【24h】

Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration

机译：丙型肝炎病毒慢性感染患者的病毒动力学在直效抗病毒剂治疗期间：监测和优化治疗持续时间的影响

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives Direct-acting antiviral agents (DAAs) have provided an ultimate treatment duration of 12 weeks for most hepatitis C virus (HCV)-infected patients. The opportunity to reduce treatment duration to 6 or 8 weeks is being evaluated. Here, the HCV viral dynamics at short times during HCV therapies and its implications for monitoring and optimizing treatment duration have been assessed.

机译：目的直接作用抗病毒剂（DAAs）为大多数丙型肝炎病毒（HCV）患者提供了12周的最终治疗持续时间。评估将治疗持续时间降至6或8周的机会。这里，已经评估了HCV疗法期间短时间的HCV病毒动态及其对监测和优化治疗持续时间的影响。

著录项

来源
《European journal of gastroenterology and hepatology》 |2017年第7期|共5页
作者
Tabernilla Andres; Grandal Marta; Pernas Berta; Castro-Iglesias Angeles; Rodriguez-Osorio Iria; Mena Alvaro; Delgado Manuel; Cid Purificacion; Pedreira Jose D.; Poveda Eva;
展开▼
作者单位

Univ A Coruna Complexo Hosp Univ A Coruna Inst Invest Biomed A Coruna Grp Virol Clin Sergas La;

Univ A Coruna Complexo Hosp Univ A Coruna Inst Invest Biomed A Coruna Grp Virol Clin Sergas La;

Univ A Coruna Complexo Hosp Univ A Coruna Inst Invest Biomed A Coruna Grp Virol Clin Sergas La;

Univ A Coruna Complexo Hosp Univ A Coruna Inst Invest Biomed A Coruna Grp Virol Clin Sergas La;

Univ A Coruna Complexo Hosp Univ A Coruna Inst Invest Biomed A Coruna Grp Virol Clin Sergas La;

Univ A Coruna Complexo Hosp Univ A Coruna Inst Invest Biomed A Coruna Grp Virol Clin Sergas La;

Univ A Coruna Complexo Hosp Univ A Coruna Inst Invest Biomed A Coruna Grp Virol Clin Sergas La;

Univ A Coruna Complexo Hosp Univ A Coruna Inst Invest Biomed A Coruna Grp Virol Clin Sergas La;

Univ A Coruna Complexo Hosp Univ A Coruna Inst Invest Biomed A Coruna Grp Virol Clin Sergas La;

Univ A Coruna Complexo Hosp Univ A Coruna Inst Invest Biomed A Coruna Grp Virol Clin Sergas La;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词
direct-acting antivirals agents; hepatitis C virus dynamics; hepatitis C virus infection; hepatitis C virus treatment;

机译：直接作用抗病毒药物;丙型肝炎病毒动态;丙型肝炎病毒感染;丙型肝炎病毒治疗;

相似文献

外文文献
中文文献
专利

1. Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration [J] . Tabernilla Andres, Grandal Marta, Pernas Berta, European journal of gastroenterology and hepatology . 2017,第7期

机译：丙型肝炎病毒慢性感染患者的病毒动力学在直效抗病毒剂治疗期间：监测和优化治疗持续时间的影响
2. Significance of day-1 viral response of hepatitis C virus in patients with chronic hepatitis C receiving direct-acting antiviral therapy [J] . Toyoda Hidenori, Kumada Takashi, Tada Toshifumi, Journal of gastroenterology and hepatology . 2018,第6期

机译：乙型肝炎病毒在慢性丙型肝炎患者接受直接抗病患者患者乙型肝炎病毒的意义
3. Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings [J] . Chen Cheng-Pin, Cheng Chien-Yu, Zou Huachun, Journal of microbiology, immunology, and infection: Wei mian yu gan ran za zhi . 2019,第4期

机译：评价PEGINTERFEREN PRIBAVIRIN在监狱和社区环境中艾滋病毒感染患者慢性丙基肝炎治疗和直接作用抗病毒剂的评价
4. MALDI-TOF MS for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy [C] . Magda Rybicka, Piotr Stalke, Tomasz Smiatacz, International Mass Spectrometry Conference . 2014

机译：MALDI-TOF MS用于监测抗病毒治疗期间乙型肝炎病毒感染患者耐药性的MS
5. Healthcare Resources Utilization, Inpatient Mortality, and Risk Behaviors among Patients Infected with Hepatitis C Virus in the United States in the Era of Direct-Acting Antivirals [D] . Alzahrani, Mohammad Saeed. 2020

机译：在直接作用抗病毒中，美国乙型肝炎病毒感染患者的医疗资源利用率，住院死亡率和风险行为
6. Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China [O] . Zhao Li, Zhi-wei Chen, Hu Li, 2017

机译：在中国西部未接受过治疗的丙型肝炎基因型1b感染患者中丙型肝炎病毒抗性联想替代药物对直接作用抗病毒药物的流行
7. IN2 Clinical Characteristics And Treatment Duration Among Patients With Chronic Hepatitis C Virus (Hcv) Infection Initiating Direct-Acting Antiviral Therapy In A Large Commercial Insurance Database In The United States [O] . Bonafede M.M., Suthoff E.D., Eynullayeva E. 2013

机译：美国大型商业保险数据库中开始直接作用抗病毒治疗的慢性丙型肝炎病毒（Hcv）感染患者的IN2临床特征和治疗持续时间
8. Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment [R] . 2010

机译：工业慢性丙型肝炎病毒感染指南：开发直接作用的抗病毒药物进行治疗

Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration

摘要

著录项

相似文献

相关主题

期刊订阅